Your browser doesn't support javascript.
loading
Clinical standards for the dosing and management of TB drugs.
Alffenaar, J W C; Stocker, S L; Forsman, L Davies; Garcia-Prats, A; Heysell, S K; Aarnoutse, R E; Akkerman, O W; Aleksa, A; van Altena, R; de Oñata, W Arrazola; Bhavani, P K; Van't Boveneind-Vrubleuskaya, N; Carvalho, A C C; Centis, R; Chakaya, J M; Cirillo, D M; Cho, J G; D Ambrosio, L; Dalcolmo, M P; Denti, P; Dheda, K; Fox, G J; Hesseling, A C; Kim, H Y; Köser, C U; Marais, B J; Margineanu, I; Märtson, A G; Torrico, M Munoz; Nataprawira, H M; Ong, C W M; Otto-Knapp, R; Peloquin, C A; Silva, D R; Ruslami, R; Santoso, P; Savic, R M; Singla, R; Svensson, E M; Skrahina, A; van Soolingen, D; Srivastava, S; Tadolini, M; Tiberi, S; Thomas, T A; Udwadia, Z F; Vu, D H; Zhang, W; Mpagama, S G; Schön, T.
Affiliation
  • Alffenaar JWC; Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW, Australia, School of Pharmacy, The University of Sydney Faculty of Medicine and Health, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia.
  • Stocker SL; School of Pharmacy, The University of Sydney Faculty of Medicine and Health, Sydney, NSW, Australia, Department of Clinical Pharmacology and Toxicology, St Vincent´s Hospital, Sydney, NSW, Australia, St Vincent´s Clinical Campus, University of NSW, Kensington, NSW, Australia.
  • Forsman LD; Division of Infectious Diseases, Department of Medicine, Karolinska Institutet, Solna, Sweden, Department of Infectious Diseases Karolinska University Hospital, Solna, Sweden.
  • Garcia-Prats A; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa, Department of Pediatrics, University of Wisconsin, Madison, WI.
  • Heysell SK; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
  • Aarnoutse RE; Department of Pharmacy, Radboud Institute for Health Sciences & Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Akkerman OW; University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands, University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands.
  • Aleksa A; Educational Institution "Grodno State Medical University", Grodno, Belarus.
  • van Altena R; Asian Harm Reduction Network (AHRN) and Medical Action Myanmar (MAM) in Yangon, Myanmar.
  • de Oñata WA; Belgian Scientific Institute for Public Health (Belgian Lung and Tuberculosis Association), Brussels, Belgium.
  • Bhavani PK; Indian Council of Medical Research-National Institute for Research in Tuberculosis-International Center for Excellence in Research, Chennai, India.
  • Van't Boveneind-Vrubleuskaya N; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, Department of Public Health TB Control, Metropolitan Public Health Services, The Hague, The Netherlands.
  • Carvalho ACC; Laboratório de Inovações em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
  • Centis R; Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy.
  • Chakaya JM; Department of Medicine, Therapeutics and Dermatology, Kenyatta University, Nairobi, Kenya, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Cirillo DM; Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Cho JG; Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, Parramatta Chest Clinic, Parramatta, NSW, Australia.
  • D Ambrosio L; Public Health Consulting Group, Lugano, Switzerland.
  • Dalcolmo MP; Reference Center Hélio Fraga, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Denti P; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Dheda K; Centre for Lung Infection and Immunity, Department of Medicine, Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa, University of Cape Town Lung Institute & South African MRC Centre for the Study of Antimicrobial Resistance, Cape Town, South Africa,
  • Fox GJ; Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia, Woolcock Institute of Medical Research, Glebe, NSW, Australia.
  • Hesseling AC; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa.
  • Kim HY; Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW, Australia, School of Pharmacy, The University of Sydney Faculty of Medicine and Health, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia.
  • Köser CU; Department of Genetics, University of Cambridge, Cambridge, UK.
  • Marais BJ; Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW, Australia, Department of Infectious Diseases and Microbiology, The Children´s Hospital at Westmead, Westmead, NSW, Australia.
  • Margineanu I; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Märtson AG; Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
  • Torrico MM; Clínica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico.
  • Nataprawira HM; Division of Paediatric Respirology, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia.
  • Ong CWM; Infectious Disease Translational Research Programme, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Institute for Health Innovation & Technology (iHealthtech), National University of Singapore, Singapore, Division of Infectious Diseases, Dep
  • Otto-Knapp R; German Central Committee against Tuberculosis (DZK), Berlin, Germany.
  • Peloquin CA; Infectious Disease Pharmacokinetics Laboratory, Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USA.
  • Silva DR; Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
  • Ruslami R; TB/HIV Research Centre, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia, Department of Biomedical Sciences, Division of Pharmacology and Therapy, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
  • Santoso P; Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia.
  • Savic RM; Department of Bioengineering and Therapeutic Sciences, Division of Pulmonary and Critical Care Medicine, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Singla R; Department of TB & Respiratory Diseases, National Institute of TB & Respiratory Diseases, New Delhi, India.
  • Svensson EM; Department of Pharmacy, Radboud Institute for Health Sciences & Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands, Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Skrahina A; The Republican Research and Practical Centre for Pulmonology and TB, Minsk, Belarus.
  • van Soolingen D; National Institute for Public Health and the Environment, TB Reference Laboratory (RIVM), Bilthoven, The Netherlands.
  • Srivastava S; Department of Pulmonary Immunology, University of Texas Health Science Center at Tyler, Tyler, TX, USA.
  • Tadolini M; Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Tiberi S; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Thomas TA; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
  • Udwadia ZF; P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India.
  • Vu DH; National Drug Information and Adverse Drug Reaction Monitoring Centre, Hanoi University of Pharmacy, Hanoi, Vietnam.
  • Zhang W; Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People´s Republic of China.
  • Mpagama SG; Kilimanjaro Christian Medical University College, Moshi, United Republic of Tanzania, Kibong´oto Infectious Diseases Hospital, Sanya Juu, Siha, Kilimanjaro, United Republic of Tanzania.
  • Schön T; Department of Infectious Diseases, Linköping University Hospital, Linköping, Sweden, Institute of Biomedical and Clinical Sciences, Division of Infection and Inflammation, Linköping University, Linköping, Sweden, Department of Infectious Diseases, Kalmar County Hospital, Kalmar, Linköping University
Int J Tuberc Lung Dis ; 26(6): 483-499, 2022 06 01.
Article in En | MEDLINE | ID: mdl-35650702
ABSTRACT

BACKGROUND:

Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim of these clinical standards is to provide guidance on 'best practice´ for dosing and management of TB drugs.

METHODS:

A panel of 57 global experts in the fields of microbiology, pharmacology and TB care were identified; 51 participated in a Delphi process. A 5-point Likert scale was used to score draft standards. The final document represents the broad consensus and was approved by all participants.

RESULTS:

Six clinical standards were defined Standard 1, defining the most appropriate initial dose for TB treatment; Standard 2, identifying patients who may be at risk of sub-optimal drug exposure; Standard 3, identifying patients at risk of developing drug-related toxicity and how best to manage this risk; Standard 4, identifying patients who can benefit from therapeutic drug monitoring (TDM); Standard 5, highlighting education and counselling that should be provided to people initiating TB treatment; and Standard 6, providing essential education for healthcare professionals. In addition, consensus research priorities were identified.

CONCLUSION:

This is the first consensus-based Clinical Standards for the dosing and management of TB drugs to guide clinicians and programme managers in planning and implementation of locally appropriate measures for optimal person-centred treatment to improve patient care.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Drug Monitoring / Antitubercular Agents Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: Int J Tuberc Lung Dis Year: 2022 Document type: Article Affiliation country: Australia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Drug Monitoring / Antitubercular Agents Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: Int J Tuberc Lung Dis Year: 2022 Document type: Article Affiliation country: Australia